LONG ACTING OCTREOTIDE IN PTS WITH DISSEMINATED NEUROENDOCRINE TUMORS

被引：0
|
作者：
Markovich, A. [1 ]
Emelianova, G. [1 ]
Gorbounova, V. [1 ]
Bruzgin, V. [1 ]
Orel, N. [1 ]
机构：
[1] NN Blokhin Russian Canc Res Ctr Ramn, Dept Chemotherapy, Moscow, Russia
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：382 / 382
页数：1
相关论文
共 50 条
  • [21] Long-acting lanreotide in the treatment of neuroendocrine tumors (NETs)
    Antonuzzo, A
    Ricci, S
    Galli, L
    Conte, PF
    ANNALS OF ONCOLOGY, 1998, 9 : 175 - 175
  • [22] Long-term experience with octreotide and lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors
    Kiesewetter, Barbara
    Pflueger, Friedrich Franz
    Melhorn, Philipp
    Mazal, Peter
    Raderer, Markus
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, : 1642 - 1652
  • [23] EFFICACY OF LONG-ACTING SOMATOSTATIN ANALOGUES (SA) IN PATIENTS (PTS) WITH HIGHLY DIFFERENTIATED GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP NETS)
    Markovich, Alla
    Galina, Emelyanova
    Vera, Gorbunova
    Nadezhda, Orel
    Alexander, Kuzminov
    Anastasia, Odintsova
    Armen, Margaryan
    ANNALS OF ONCOLOGY, 2014, 25
  • [24] Comparative Analysis of Octreotide Long Acting Release (LAR) and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): A Single Institution Experience
    Wu, S.
    Reta-Impey, P.
    Manivannan, N.
    Tirumani, S. H.
    Fu, P.
    Cao, S.
    Asa, S.
    Kardan, A.
    Liu, F.
    Avril, N.
    Wojtylak, P.
    Lee, R.
    Bajor, D.
    Selfridge, E.
    Saltzman, J.
    Hardacre, J.
    Ammori, J.
    Winter, J.
    Mohamed, A.
    PANCREAS, 2021, 50 (03) : 448 - 449
  • [25] Efficace of long-acting somatostatin analogues (SA) in patients (pts) with highly differentiated gastroenteropancreatic neuroendocrine tumors (GEP NETs)
    Markovich, Alla
    Nadezhda, Orel
    Armen, Margaryan
    Alexander, Kuzminov
    Galina, Emelyanova
    Anastasia, Odintsova
    Vera, Gorbunova
    ANNALS OF ONCOLOGY, 2017, 28
  • [26] Real-World Comparative Analysis of Lanreotide and Octreotide Long-Acting Release (Lar) Use for Neuroendocrine Tumors (NETS) in Canada
    Loree, Jonathan
    Feuilly, Marion
    Laforty, Callahan
    Liovas, Anna
    McKechnie, Heather
    Cheung, Winson
    PANCREAS, 2020, 49 (03) : 477 - 477
  • [27] Everolimus in Combination with Octreotide Long-Acting Repeatable in a First-Line Setting for Patients With Neuroendocrine Tumors An ITMO Group Study
    Bajetta, Emilio
    Catena, Laura
    Fazio, Nicola
    Pusceddu, Sara
    Biondani, Pamela
    Blanco, Giusi
    Ricci, Sergio
    Aieta, Michele
    Pucci, Francesca
    Valente, Monica
    Bianco, Nadia
    Mauri, Chiara Maria
    Spada, Francesca
    CANCER, 2014, 120 (16) : 2457 - 2463
  • [28] Long-acting octreotide treatment has no impact on tumor uptake of 99mTc-HYNIC-TOC in patients with neuroendocrine tumors
    Li, Yi
    Xu, Junyan
    Xu, Xiaoping
    Zhang, Jiangang
    Zhang, Yingjian
    NUCLEAR MEDICINE COMMUNICATIONS, 2019, 40 (10) : 1005 - 1010
  • [29] Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors
    Al-Efraij, Khalid
    Aljama, Mohammed A.
    Kennecke, Hagen Fritz
    CANCER MEDICINE, 2015, 4 (06): : 864 - 870
  • [30] Everolimus plus octreotide long-acting repeatable in advanced neuroendocrine tumors in the routine tertiary cancer care setting: An Indian experience
    Tippeswamy, R.
    Patil, S.
    Sateesh, C. T.
    Shashidhara, H. P.
    Prabhudesai, S.
    Prashanth, P.
    Haridas, K. M.
    INDIAN JOURNAL OF CANCER, 2015, 52 (03) : 359 - U136
12345